Cemiplimab is a humanized anti-PD-1 monoclonal antibody approved for first-line treatment of NSCLC with high PD-L1 (≥50%) and no EGFR, ALK, or ROS1 aberrations, used alone or with platinum-based chemotherapy in advanced or metastatic cases in patients unsuitable for surgery or definitive chemoradiation [38]. Here, CD274 is linked to non-small cell lung carcinoma.